VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the closing of a $4.545 million bridge financing through the offer of convertible notes and warrants..

不列颠哥伦比亚省温哥华市——（商业新闻短讯）——阿尔法认知公司（CSE:ACOG）（OTCQB:ACOGF）（“阿尔法认知”或“公司”）是一家致力于开发治疗神经退行性疾病的新型疗法的生物制药公司，今天宣布通过提供可转换票据和认股权证，完成454.5万美元的过桥融资。。

The financing was led by existing investors and select new investors comprised of institutional funds and high-net-worth accredited individuals. The Benchmark Company, LLC acted as the sole placement agent for the offering. The Kestrel Merchant Partners group at The Benchmark Company, LLC was responsible for sourcing and executing the offering..

融资由现有投资者和精选的新投资者主导，新投资者由机构基金和高净值认证个人组成。Benchmark Company，LLC是此次发售的独家配售代理。Benchmark Company，LLC的Kestrel Merchant Partners group负责采购和执行此次发售。。

The notes are convertible into common shares of the Company at a conversion price of $0.422 per share. The notes mature on September 24, 2026, have an aggregate face value of $4.545 million and bear interest at a rate of 10% per annum paid in common shares of the Company at the conversion price, subject to certain limitations..

票据可转换为公司普通股，转换价格为每股0.422美元。。。

The notes are subject to mandatory conversion into common shares of the Company in conjunction with the closing of an offering of securities of the Company for at least $10 million in aggregate gross proceeds in coordination with the simultaneous uplisting of the common shares of the Company onto a United States national securities exchange (a “Qualified Offering”).

票据须强制转换为本公司普通股，同时完成本公司证券发行，总收益至少为1000万美元，同时将本公司普通股同时上架至美国国家证券交易所（“合格发行”）。

Such conversion will be completed into the securities offered in such Qualified Offering at the lower of (i) the conversion price in effect at such time and (ii) the offering price of the securities in the Qualified Offering..

此类转换将以（i）当时有效的转换价格和（ii）合格发行中证券的发行价格中较低的价格完成。。

If, prior to the completion of a Qualified Offering, the common shares of the Company close at a price of at least 250% of the conversion price for 10 consecutive trading days and the common shares issuable upon such conversion are registered for resale under the United States Securities Act of 1933, as amended (the “U.S.

如果在合格发行完成之前，公司的普通股连续10个交易日以至少250%的转换价格收盘，并且转换后可发行的普通股根据1933年《美国证券法》修订版（“美国证券法”）登记转售。

Securities Act”), then the notes will automatically convert into common shares at the conversion price..

《证券法》），则票据将按转换价格自动转换为普通股。。

The notes are unsecured and rank senior to the Company’s other indebtedness.

票据为无担保票据，优先于公司的其他债务。

The notes were sold along with warrants to purchase common shares of the Company at an exercise price of $0.422 for a five-year term. Each investor received warrants sufficient to purchase such number of common shares equal to the principal amount of notes such investor purchased divided by the conversion price of the notes.

这些票据与认股权证一起出售，以0.422美元的行权价格购买该公司的普通股，为期五年。每位投资者收到的认股权证足以购买该数量的普通股，该数量等于该投资者购买的票据的本金除以票据的转换价格。

Each investor will receive an additional 50% of warrants with identical terms upon the closing of a Qualified Offering, as described above. The exercise price of the warrants is subject to adjustment upon the completion of a Qualified Offering to the lower of (i) the then existing exercise price, (ii) the exercise price of any common share purchase warrants issued in the Qualified Offering or (iii) if no common share purchase warrants are issued in the Qualified Offering, the closing price of the common shares on the Canadian Securities Exchange (as converted into U.S.

如上所述，在合格发行结束后，每位投资者将获得额外50%的条款相同的认股权证。合格发行完成后，认股权证的行权价格可调整为（i）当时的行权价格，（ii）合格发行中发行的任何普通股认购权证的行权价格，或（iii）如果合格发行中未发行普通股认购权证，则为加拿大证券交易所普通股的收盘价格（转换为美国。

dollars) immediately prior to the pricing news release of the Qualified Offering..

美元）在合格发行的定价新闻发布之前。。

Proceeds from the bridge financing will be utilized to continue commercialization work for the Company’s recently approved drug ZUNVEYL™, to complete payer pricing and contracting work, and to manufacture commercial product.

过桥融资的收益将用于继续该公司最近批准的药物ZUNVEYL™的商业化工作，完成付款人定价和承包工作，以及制造商业产品。

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S.

本新闻稿不构成在美国出售或邀请购买任何证券的要约。这些证券尚未也不会根据《美国证券法》或任何州证券法进行登记，也不可能在美国境内或为美国的账户或利益而提供或出售。

Persons unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available. “United States” and “U.S. Person” are as defined in Regulation S under the U.S. Securities Act. In connection with the bridge financing, the Company also entered into a registration rights agreement with the investors pursuant to which the Company agreed to file a registration statement with the SEC under the U.S.

除非根据1933年法案和适用的州证券法进行登记，或者可以免除此类登记。“美国人”和“美国人”的定义见《美国证券法》S条例。关于过桥融资，公司还与投资者签订了登记权协议，根据该协议，公司同意根据美国证券交易委员会的规定向美国证券交易委员会提交登记声明。

Securities Act, covering the resale of the shares issuable upon conversion of the convertible notes and exercise of the warrants by the investors..

《证券法》，涵盖可转换票据转换后可发行股票的转售以及投资者行使认股权证。。

About Alpha Cognition Inc.

关于Alpha认知公司。

Alpha Cognition Inc. is a commercial, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease following the recent New Drug Application (the “NDA”) submission and acceptance by FDA..

Alpha认知公司是一家商业生物制药公司，致力于为患有神经退行性疾病（如阿尔茨海默氏病）的患者开发治疗方法，这些疾病的治疗选择有限或没有。在最近的新药申请（“NDA”）提交并被FDA接受后，该公司专注于开发用于治疗轻度至中度阿尔茨海默氏病的ALPHA-1062。。

ALPHA-1062 is a patented new innovative product being developed as a next generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.

ALPHA-1062是一种获得专利的新创新产品，正在开发作为下一代乙酰胆碱酯酶抑制剂，用于治疗阿尔茨海默病，预计胃肠道副作用最小。ALPHA-1062的活性代谢物与多奈哌齐和利凡斯的明的区别在于它结合神经元烟碱受体，最明显的是α-7亚型，已知其对认知有积极影响。

ALPHA-1062 is in development in combination with memantine to treat moderate to severe Alzheimer’s disease, in development with sublingual formulation for patients suffering from dysphagia and is being out-licensed to study an intranasal formulation for cognitive impairment with mTBI (otherwise known as concussion)..

ALPHA-1062正在与美金刚联合开发，用于治疗中度至重度阿尔茨海默病，正在开发用于吞咽困难患者的舌下制剂，并且正在被授权研究用于mTBI认知障碍（也称为脑震荡）的鼻内制剂。。

Neither Canadian Securities Exchange (the “CSE”) or the OTC Markets Group, accepts responsibility for the adequacy or accuracy of this release.

加拿大证券交易所（“CSE”）或OTC市场集团均不对本次发布的充分性或准确性承担责任。

Forward-looking Statements

前瞻性声明

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward-looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

本新闻稿包括适用证券法意义上的前瞻性声明。。

In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future.

在某些情况下，您可以通过“可能”、“可能”、“将”、“可能”、“应该”、“预期”、“打算”、“计划”、“目标”、“预期”、“相信”、“估计”、“预测”、“项目”、“潜在”、“目标”、“寻求”、“沉思”、“继续”和“正在进行”等词语来识别前瞻性陈述，或者这些术语的否定词，或者其他旨在识别未来陈述的类似术语。

Forward-looking statements may include statements regarding the use of proceeds from the bridge financing, the Company’s timing and planned activities to launch ZUNVEYL, potential timing for the availability of ZUNVEYL, potential future developments of ZUNVEYL, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products.

前瞻性陈述可能包括关于过桥融资收益的使用、公司推出ZUNVEYL的时间和计划活动、ZUNVEYL可用的潜在时间、ZUNVEYL的潜在未来发展、公司的商业战略、市场规模、潜在增长机会、资本要求、临床开发活动、临床试验的时间和结果、监管提交、潜在监管批准和公司产品的商业化等方面的陈述。

Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company.

尽管本公司认为每个前瞻性陈述都有合理的依据，但我们提醒您，这些陈述是基于我们目前已知的事实和因素以及我们对未来的预期，对此我们无法确定。公司。